These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34970781)

  • 1. An Empirical Analysis of Japan's Drug Development Lag Behind the United States.
    Nakamura H; Wakutsu N; Murayama S; Suzuki T
    J Clin Pharmacol; 2022 Jul; 62(7):847-854. PubMed ID: 34970781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Development Strategies Affecting Japan's Drug lag between Japan-Based and Foreign-Based Companies.
    Hidaka M; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2024 Jul; 58(4):714-720. PubMed ID: 38575785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
    Maeda H; Kurokawa T
    Int J Clin Oncol; 2015 Dec; 20(6):1072-80. PubMed ID: 25837976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.
    Honig PK
    Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
    Nakayama H; Matsumaru N; Tsukamoto K
    Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US.
    Maki A; Narukawa M
    Ther Innov Regul Sci; 2023 Jul; 57(4):671-677. PubMed ID: 36966205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lag Time for New Innovative, First-in-Class, Drug Approval in Japan.
    Miyazaki T; Komiyama M; Matsumaru N; Maeda H; Tsukamoto K
    Biol Pharm Bull; 2022; 45(4):477-482. PubMed ID: 35370272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017.
    Lee SW; Park SH; Song I; Noh Y; Park H; Ha D; Shin JY
    Ther Innov Regul Sci; 2020 Mar; 54(2):418-423. PubMed ID: 32072585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan.
    Ueno T; Asahina Y; Tanaka A; Yamada H; Nakamura M; Uyama Y
    Clin Pharmacol Ther; 2014 May; 95(5):533-41. PubMed ID: 24213186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncology drug lag in Japan: has it improved over the last decade?
    Tachibana Y; Narukawa M
    Int J Clin Oncol; 2023 Nov; 28(11):1451-1460. PubMed ID: 37561368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The notorious "drug lag" for oncology drugs in Japan.
    Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
    Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies.
    Han Y; Jiang R; Li J; Wang Y; Shao R; Xie J
    Clin Pharmacol Ther; 2024 Jun; 115(6):1400-1407. PubMed ID: 38429944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to Innovative Medicines: Regulation Change and Factors Associated with Drug Approval Lag in Malaysia.
    Chow WL; Salleh NAM; Kang TS
    Ther Innov Regul Sci; 2024 May; 58(3):528-538. PubMed ID: 38376698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials.
    Ushijima S; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2021 Jul; 35(4):253-260. PubMed ID: 34291425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Pediatric Drug Approval Lag in Japan.
    Ueyama E; Kaneko M; Narukawa M
    Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States.
    Maeda H; Kurokawa T
    J Clin Pharmacol; 2015 May; 55(5):481-9. PubMed ID: 25560978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study.
    Maeda H; Hara A; Ofuchi M; Shingai R; Misumi T; Murai Y
    Clin Transl Sci; 2023 Dec; 16(12):2665-2674. PubMed ID: 37815272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Delays in clinical development of neurological drugs in Japan].
    Ikeda M
    Rinsho Shinkeigaku; 2017 Jun; 57(6):274-279. PubMed ID: 28552868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.